Medicenna Therapeutics (TSE:MDNA) Shares Down 8.7% – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price fell 8.7% on Wednesday . The stock traded as low as C$1.45 and last traded at C$1.47. 343,420 shares changed hands during trading, an increase of 503% from the average session volume of 56,998 shares. The stock had previously closed at C$1.61.

Medicenna Therapeutics Stock Down 13.0%

The firm has a 50-day moving average of C$1.31 and a two-hundred day moving average of C$1.08. The stock has a market capitalization of C$116.78 million, a price-to-earnings ratio of -8.24 and a beta of 3.31. The company has a quick ratio of 4.65, a current ratio of 11.40 and a debt-to-equity ratio of 0.88.

Medicenna Therapeutics (TSE:MDNA) last released its earnings results on Thursday, November 13th. The company reported C($0.06) earnings per share for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 159.88%. As a group, sell-side analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.